KRAS and neoplasm: The improvement in outcomes in the wild-type RAS population vs the wild-type KRAS exon 2 population is also consistent with that seen in extended RAS analysis of the PRIME study in the first-line setting (Douillard et al, 2013) and the 20050181 study in the second-line setting (Peeters et al, 2015), indicating the benefit observed in patients with tumours without activating RAS mutations is true across all lines of therapy and for combination treatment as well as monotherapy.